Search Browse Earnings

Chemomab Therapeutics Ltd. — SlamSEC

Chemomab Therapeutics Ltd.

Nasdaq:CMMB

Pharmaceutical Preparations·TEL AVIV

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$102.9M

FY 2024

Net Income

-$27.6M

FY 2024

EPS (Diluted)

$0.12

FY 2024

Stock Price

$2.00

+6.4%

2026-03-09

52W Range

$1.35 – $6.10

P/E Ratio

16.5x

Market Cap

$754.3M

Cash

$9.3M

FY 2024

Total Debt

—

Net Cash

$9.3M

Enterprise Value

$745.0M

Debt / EBITDA

0.1x

FY 2024

EV / EBITDA

-7.2x

Employees

—

CFO

Fatal Sigal